Ohio State Navbar

Clinical Trials


 

 

If you would like more information or are interested in referring a patient to one of these trials, click on the PI's name to generate a contact email or call The James Line at 1-800-293-5066.  To search all cancer clinical trials available at Ohio State, visit cancer.osu.edu.


 

Recently Opened Trials

Breast

  • Phase I, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884), and to Estimate the Maximum Tolerated Dose in Subjects With Advanced or Refractory Cancer
    OSU-15281 (Robert Wesolowski, MD)
     

Gastrointestinal

  • Phase II Single-Arm Study of Regorafenib Maintenance Therapy in Patients With T3, T4 or Node-positive Rectal Cancer Who Completed Curative-Intent Treatment
    OSU-15017 (Christina Wu, MD)
     
  • Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined With mFOLFOX6 as First Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
    OSU-15197 (Sameh Mikhail, MB/BCH)

Genitourinary

  • Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients With High-Grade Upper Tract Urothelial Carcinoma
    ECOG-EA8141 (Megan Merrill, DO)


Head and Neck

  • Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Effects of Intravenous GC4419 on the Incidence and Duration of Severe Oral Mucositis (OM) in Patients Receiving Post-Operative or Definitive Therapy With Single-Agent Cisplatin Plus IMRT for Locally Advanced, Non-Metastatic Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
    OSU-15198 (Dukagjin Blakaj, MD, PhD)


Melanoma


Neuroendocrine

  • Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)
    OSU-15244 (Manisha Shah, MD)


Thoracic

  • Randomized Phase III Study of Sublobar Resection (SR) vs. Stereotactic Ablative Radiotherapy (SAbR) in High-Risk Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
    OSU-15158 (Terence Williams, MD, PhD)
     
  • Phase 1b, Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-Small Cell Lung Cancer 
    OSU-15265 (Greg Otterson, MD)

 

Immune Therapy Trials
 

Breast

  • Phase I, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884) and to Estimate the Maximum Tolerated Dose in Subjects With Advanced or Refractory Cancer
    OSU-15281 (Robert Wesolowski, MD)


Melanoma

  • Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
    ECOG-EA6134 (Joanne Jeter, MD)
     
  • Phase II Study Using Stereotactic Ablative Radiation Therapy and Ipilimumab in Patients With Oligometastatic Melanoma
    OSU-12182 (Evan Wuthrick, MD)

Genitourinary

  • Open-label, Multicenter, Expanded-Access Program for Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy
    OSU-15122 (Amir Mortazavi, MD)
     
  • Phase I Study of (Cabozantinib) Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
    OSU-15150 (Amir Mortazavi, MD


Gynecologic

  • Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
    NRG-GY002 (David O’Malley, MD)
     
  • Phase I Open-label, Multiple-Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
    OSU-13257 (John Hays, MD, PhD)
     
  • Phase II Proof-of-Concept Study of ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer
    OSU-15207 (Floor Backes, MD)

Gastrointestinal

  • Phase II Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors
    OSU-14006 (Richard Goldberg, MD)
     
  • Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumors
    OSU-14018 (Kristen Ciombor, MD)
     
  • Phase I, Open-Label, Multicenter Safety Study of Nivolumab (BMS-936558) in Combination With  nab-Paclitaxel Plus or Minus  Gemcitabine in Pancreatic Cancer, nab-PACLITAXEL / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer, or nab-Paclitaxel in Recurrent Metastatic Breast Cancer
    OSU-14250 (Christina Wu, MD)
     
  • Phase I, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Antitumor Activity of MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors
    OSU-15169 (Christina Wu, MD)
     
  • Multicenter, Single-Arm, Phase II Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer: HCRN GI14-186
    OSU-15090 (Anne Noonan, MB/BCH)


Head and Neck

  • Phase III, Randomized, Open-label, Multicenter, Global Study of MEDI4736 Alone or in Combination With Tremelimumab vs. Standard-of-Care in the Treatment of First-Line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients
    OSU-15210 (Maura Gillison, MD, PhD)


Melanoma

  • Phase III, Randomized, Double-Blind Study of Adjuvant Immunotherapy With Nivolumab vs. Ipilimumab After Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects at High Risk for Recurrence
    OSU-15130 (Kari Kendra, MD, PhD)
     
  • Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
    SWOG-S1404 (Kari Kendra, MD, PhD)

Neuroendocrine

  • Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)
    OSU-15244 (Manisha Shah, MD)

Thoracic

  • Open-label, Randomized, Phase III Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy vs. Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
    OSU-15127 (Greg Otterson, MD)
     
  • Randomized, Multicenter, Double-blind, Phase III Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small-Cell Lung Cancer (ED-SCLC) After Completion of Platinum-Based First Line Chemotherapy
    OSU-15171 (Greg Otterson, MD)

 

Updated: 5/26/16

 

 

© 2016 The Ohio State University Comprehensive Cancer Center –
James Cancer Hospital and Solove Research Institute
460 W. 10th Avenue
Columbus, Ohio 43210

cancer.osu.edu

Jamesline Blog  Facebook  Twitter  LinkedIn  Google+  Instagram  YouTube  Pinterest  Cancer Connect